What are the key leadership changes at Vertex Pharmaceuticals?

Matthew Emmens has been appointed President and will become CEO and Chairman of the Board on May 23, 2009. Dr. Joshua Boger will transition from CEO and President to remain a board member, with his CEO tenure ending May 23, 2009. Dr. Charles Sanders will move from Chairman to lead outside director.

What is the compensation package for the new President, Matthew Emmens?

Matthew Emmens will receive an initial annual salary of $1,100,000, with a target annual cash bonus of 115% of his base salary. He has also been granted options to purchase 549,000 shares of common stock and 134,129 restricted shares, subject to vesting conditions.

What are the terms of Joshua Boger's transition agreement?

Dr. Joshua Boger's employment will conclude on May 23, 2009. Upon his departure, he is entitled to a lump sum payment of approximately $2.85 million, 18 months of accelerated vesting for his stock options and restricted stock awards, and reimbursement for certain expenses. Enhanced provisions apply in the event of a change of control.

Were there any changes to Vertex's stock option plans?

Yes, the Amended and Restated 2006 Stock and Option Plan was amended to increase the maximum number of shares that can be issued to a participant in a calendar year from 600,000 to 700,000.

VRTX 8-K: Leadership Changes & Material Agreements

Summary

Vertex Pharmaceuticals Incorporated filed an 8-K on February 10, 2009, reporting significant leadership changes and an amendment to its stock plan. Effective February 5, 2009, Matthew Emmens was appointed President and is slated to become CEO and Chairman of the Board on May 23, 2009. This transition involves the departure of Dr. Joshua Boger as President and CEO, though he will remain CEO until May 23, 2009, and continue as a board member. Dr. Charles Sanders will transition from Chairman to lead outside director. These leadership changes are accompanied by detailed compensation and severance agreements for both Mr. Emmens and Dr. Boger. Mr. Emmens receives a substantial salary, bonus potential, stock options, and restricted stock grants, along with provisions for severance and accelerated vesting in cases of termination or change of control. Dr. Boger's transition agreement outlines a significant severance payment, accelerated vesting of equity, and provisions for change of control scenarios.

Key Highlights

1Vertex Pharmaceuticals announced a leadership transition with Matthew Emmens appointed President, and set to become CEO and Chairman on May 23, 2009.
2Dr. Joshua Boger will step down as President and CEO on May 23, 2009, but will remain a board member.
3Charles Sanders, M.D., current Chairman, will transition to lead outside director.
4Matthew Emmens' compensation package includes a $1.1 million base salary, a target bonus of 115% of base salary, 549,000 stock options, and 134,129 restricted shares.
5Generous severance packages are in place for both Mr. Emmens and Dr. Boger, including provisions for termination without cause, termination for good reason, and change of control events.
6The company amended its 2006 Stock and Option Plan to increase the maximum annual shares issuable to a participant from 600,000 to 700,000.

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Material Agreement (Feb 10, 2009)

Summary

Key Highlights

Frequently Asked Questions